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Abstract
Alport syndrome (AS) is an inherited progressive renal disease caused by mutations in
COL4A3, COL4A4, and COL4A5 genes. Despite simultaneous screening of these genes
being widely available, mutation detection still remains incomplete in a non-marginal portion
of patients. Here, we applied whole-exome sequencing (WES) in 3 Italian families negative
after candidate-gene analyses. In Family 1, we identified a novel heterozygous intronic
variant (c.2245-40A>G) -outside the conventionally screened candidate region for diagno-
sis- potentially disrupting COL4A5 exon29 splicing. Using a minigene-based approach in
HEK293 cells we demonstrated that this variant abolishes exon29 branch site, causing exon
skipping. Moreover, skewed X-inactivation of the c.2245-40A>G allele correlated with dis-
ease severity in heterozygous females. In Family 2, WES highlighted a novel COL4A5
hemizygous missense mutation (p.Gly491Asp), which segregates with the phenotype and
impacts on a highly-conserved residue. Finally, in Family 3, we detected a homozygous 24-
bp in-frame deletion in COL4A3 exon1 (NM_000091.4:c.30_53del:p.Val11_Leu18del or
c.40_63del24:p.Leu14_Leu21del), which is ambiguously annotated in databases, although
it corresponds to a recurrent AS mutation. Functional analyses showed that this deletion
disrupts COL4A3 signal peptide, possibly altering protein secretion. In conclusion, WES
-together with functional studies- was fundamental for molecular diagnosis in 3 AS families,
highlighting pathogenic variants that escaped previous screenings.
Introduction
Alport syndrome (AS) is a rare inherited disease of the glomerular basement membrane (GBM)
with a prevalence of 1–10:50,000 live births in different populations [1] and characterized by







Citation: Chiereghin C, Robusto M, Mastrangelo A,
Castorina P, Montini G, Giani M, et al. (2017) Alport
syndrome cold cases: Missing mutations identified
by exome sequencing and functional analysis.
PLoS ONE 12(6): e0178630. https://doi.org/
10.1371/journal.pone.0178630
Editor: Emanuele Buratti, International Centre for
Genetic Engineering and Biotechnology, ITALY
Received: March 1, 2017
Accepted: May 16, 2017
Published: June 1, 2017
Copyright: © 2017 Chiereghin et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The study was supported by the Italian
Telethon Foundation grant GGP11177 (to Prof
Stefano Duga) and Fondazione Cariplo grant N.
2013-0825 (to Prof Rosanna Asselta). The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
hematuria, with first onset usually in childhood, proteinuria, and progressive renal failure.
Extrarenal signs might also be present, including sensorineural hearing loss and ocular anoma-
lies, such as anterior lenticonus, cataract, and maculopathy [2]. AS is caused by mutations in
the COL4A3,COL4A4, and COL4A5 genes, encoding the α3, α4, and α5 chains of collagen type
IV, a major structural component of the GBM, as well as of the basement membranes in the
cochlea and eye. Kashtan and colleagues [2] recently reported that ~65% of AS cases are X-
linked (MIM#301050, COL4A5mutations), 20% are autosomal dominant (MIM#104200,
COL4A3 or COL4A4 heterozygous mutations), and the remaining 15% are autosomal recessive
(MIM#203780, biallelic mutations in COL4A3 or COL4A4). Previously, autosomally dominant
inherited forms were considered rare [1]. In a small number of cases, evidence for digenic
inheritance of AS has also been reported [3].
Some heterozygous mutations in COL4A3 and COL4A4 genes can cause a milder pheno-
type, defined as thin basement membrane nephropathy (TBMN; MIM#141200, or benign
familial hematuria), which is characterized by persistent microscopic hematuria although
rarely combined with progressive proteinuria and end-stage renal disease [4].
AS shows high inter- and intra-familial phenotypic variability, as well as high allelic hetero-
geneity [5]. Indeed, >900 different mutations have been collectively reported in the three col-
lagen IV genes (Human Gene Mutation Database, HGMD: http://hgmd.cf.ac.uk, last accessed
October 2016). In addition, these genes are large -comprising 52, 48, and 51 coding exons for
COL4A3,COL4A4, and COL4A5, respectively- thus hindering comprehensive genetic screen-
ings in large patient series. To further complicate the scenery, genetic variations in modifier
genes, such as NPHS2 (encoding podocin), may modify disease severity in patients who have
at least one mutation in a type IV collagen gene [6].
In recent years, the introduction of next-generation sequencing (NGS) has made possible
the time- and cost-effective analysis of all three AS genes in a single step [7,8]. Despite these
technological advancements, the total mutation detection rate ranged from 55 to 80%,
meaning that at least a fifth of the patients still remains without a molecular diagnosis [8,9].
Unequivocal -and possibly early- molecular diagnosis is extremely important for prognostic
assessment and genetic counseling.
Reasons for missing pathogenic mutations by NGS can be multiple. For example, GC-rich
exons may fail capture or amplification and subsequent sequencing. Moreover, the presence of
homopolymeric repeats might be a specific issue when using certain NGS platforms [10]. In
addition, detection of small insertion-deletions (indels) and gene rearrangements is known to
be less accurate than single nucleotide variants [8]. Finally, deep-intronic and promoter muta-
tions can be missed by routine screening as well as standard NGS data analysis, since they are
mostly focused on coding exons and splice sites.
Recently, whole-exome sequencing (WES) has been proposed as an alternative approach in
cases negative for gene-specific screenings [8,9]. The existence of additional so-far unknown
genes for Alport and Alport-like disease has also been suggested [9].
Here, we applied WES to identify the genetic basis of AS in three Italian families with clear
clinical evidence but no molecular diagnosis, despite having been subjected to extensive analy-
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Helsinki. Signed informed consent was obtained from all participants and from parents of sub-
jects younger than 18 years.
Genomic DNA was extracted from peripheral blood using an automated DNA extractor
Maxwell 16 system (Promega, Madison, WI), and quantified on a Nanodrop ND-1000 spectro-
photometer (NanoDrop Technologies, Wilmington, DE).
Three Italian families were included in this study. Diagnosis of AS was primarily based on
renal biopsy, which showed pathognomonic ultrastructural abnormalities in the GMB, such
as thickening, splitting, and reticulation, as well as on at least two other criteria, including: i)
family history of hematuria, chronic kidney disease or AS; ii) SHL; and/or iii) specific ocular
anomalies (Table 1).
The probands from the three families were previously subjected to several genetic screen-
ings, as reported in S1 Table.
Whole-exome sequencing
WES was performed on the three probands (P1-P3, Fig 1). Sequencing libraries were prepared
starting from 50 ng of genomic DNA using the Nextera Rapid Capture Exome Enrichment
kit (Illumina, San Diego, CA), following the manufacturer’s instructions, and run as 150-bp
paired-end reads on a NextSeq500 (Illumina).
Reads were aligned to the human reference genome (hg19, GRCh37 build) using the Bur-
rows-Wheeler Aligner (BWA) version 0.7.7 program [11], duplicates were marked with Picard
v.1.79 and genotypes at variant positions (both single nucleotide variants and indels) were
called using GATK v.1.6–23 [12].
Variant annotation and prioritization is detailed in Supporting Methods. Variant analysis
primarily focused on COL4A3,COL4A4, and COL4A5. Both exonic and intronic variants were
evaluated.
Sanger sequencing
COL4A5 exons 29 (including flanking intronic sequences) and 33, as well as COL4A3 exon 1
were PCR amplified using sets of primers designed on the basis of the known genomic sequence
of the gene (GenBank accession numbers NM_000495.4 and NM_000091.4). PCRs were per-
formed on 10–20 ng of genomic DNA, following standard procedures. Primer sequences and
specific PCR conditions are available on request. Direct sequencing of amplified fragments was
performed on both strands with the BigDye Terminator Cycle Sequencing Ready Reaction Kit
v.1.1 and an automated ABI-3500DX DNA sequencer (Applied Biosystems, Foster City, CA).
The Variant Reporter software (Applied Biosystems) was used for variant detection.
In-silico analyses
Branch-point sequence analysis of the wild-type and mutant COL4A5 intron 28-exon 29
boundary was performed using the Human Splicing Finder software (http://www.umd.be/
HSF3/, last accessed October 2016).
Table 1. Patient characteristics.
Patient Gender Age Family history Proteinuria/creatinuria GBM changes Renal function Hearing loss Ocular lesions
P1 F 47 AS 0.4 Thinning, thickening Normal N N
P2 M 20 HE, SHL >2 Thinning, thickening, splitting CKD Y N
P3 F 25 HE >1 Thinning, thickening, splitting Normal Y Y
AS: Alport syndrome; HE: hematuria, SHL: Sensorineural Hearing Loss; CKD: Chronic Kidney Disease; F: female; M: male; N: no; Y: yes.
https://doi.org/10.1371/journal.pone.0178630.t001
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Fig 1. Identification of candidate COL4A5 and COL4A3 variants segregating with Alport syndrome in three Italian families.
Pedigrees of Family 1 (A, X-linked), 2 (B, X-linked), and 3 (C, autosomal recessive) showing the segregation of the identified variants with
AS. Individuals analyzed by WES are pointed by an arrow. The genotype of available individuals from each family is indicated below the
corresponding symbols and illustrative electropherograms are shown on the right. M, mutant; W, wild type; R, A or G; S, G or C; Y, C or T;
CKD, chronic kidney disease.
https://doi.org/10.1371/journal.pone.0178630.g001
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Signal-peptide prediction of wild-type and mutant COL4A3 amino acid sequences was per-
formed using SignalP 4.1, PrediSi, and Signal-3L 2.0 (http://www.cbs.dtu.dk/services/SignalP/,
http://www.predisi.de/, http://www.csbio.sjtu.edu.cn/bioinf/Signal-3L/, last accessed October
2016)
Potential pathogenicity of the candidate COL4A5missense variant was assessed using:
SIFT, MutationTaster2, PolyPhen-2, MutationAssessor, FATHMM, Likelihood Ratio Test
(LRT), Condel, Provean, and CADD [13–21].
Expression vector preparation
For the functional characterization of the candidate branch-site mutation in COL4A5, the rele-
vant genomic DNA region was cloned in the hybrid alpha-globin-fibronectin minigene plas-
mid (modified pBS-KS), as previously described [22]. In particular, a 543-bp fragment of
COL4A5 (including the entire exon 29 and flanking intronic regions) was PCR amplified from
the patient’s genomic DNA using the following primers: COL4A5_ex29_NdeI_F 5’-ggaa
ttccatatgACCCTGTTTCCAATCCTTCCA-3’ and COL4A5_ex29_NdeI_R 5’-ggaattc
catatgGCCGGGCCATGATTTTATT-3’ (lowercase letters indicate nucleotides added to the
primers to introduce the NdeI restriction site) and cloned into the modified pBS-KS vector.
For the functional characterization of the COL4A3 signal-peptide deletion, the genomic
DNA region coding for the predicted signal peptide was PCR amplified from the patient’s
genomic DNA (with primers including XhoI and KpnI restriction sites: COL4A3_SP_F 5’-
ggcctcgaGGTGGCCTGAGAGCCTGA-3’ and COL4A3_SP_R 5’-agaggtaccTGGAGGA
GGGATGGAAGTG-3’) and cloned in-frame upstream of the EGFP (Enhanced Green Fluores-
cent Protein) coding region in the pEGFP-N1 plasmid (Clontech, Mountain View, CA).
Recombinant plasmids were extracted with the PureYield Plasmid Midiprep System (Pro-
mega), and verified by sequencing.
Cell cultures and transfection experiments
HEK293 cells were cultured in Dulbecco’s Modified Eagle medium containing 2 mM L-gluta-
mine, 10% fetal bovine serum and antibiotics (100 U/ml penicillin and 100 μg/ml streptomy-
cin; Euroclone, Wetherby, UK) and grown at 37˚C in a humidified atmosphere of 5% CO2 and
95% air, according to standard procedures.
For splicing assays on COL4A5 exon 29, an equal number of cells (3x105) were transiently
transfected with 1 μg of either the wild-type or the mutant recombinant vector using the Jet-
PRIME reagent (Euroclone), as described by the manufacturer.
Similarly, for localization analyses, 2.5x105 HEK293 cells were seeded on 22x22 mm glass
coverslips and transfected with 1 μg of either the wild-type (COL4A3-SP-wt-hybEGFP) or
the deleted (COL4A3-SP-del-hybEGFP) recombinant vector. As positive control, the empty
pEGFP-N1 plasmid, expressing a soluble EGFP, was used. Cells were fixed 24 hours after
transfection using 4% paraformaldehyde, permeabilized, and mounted with ProLong Dia-
mond Antifade Mountant with DAPI (Molecular Probes, Eugene, OR). Confocal images
were acquired using a 60x UPLSAPO oil-immersion objective (N.A. 1.35, Olympus, Shinjuku,
Tokyo, Japan) with an Olympus FluoView FV1000 confocal microscope at a resolution of 1
airy unit. The fluorescence resulting from the sequential excitation at 405 (Diode laser) and
488 (Argon ion laser) nm was collected with 425–475 (for DAPI) and 500–600 (for EGFP) nm
band-pass filters. Identical gain, offset, exposure, and laser-power settings were applied to all
acquisitions.
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Splicing analyses
Total RNA was isolated from cells 24 hours after transfection, using the EuroGold TriFast
reagent (Euroclone). Random hexamers and the ImProm-II Reverse Transcriptase (Promega)
were used to perform first-strand cDNA synthesis, starting from 500 ng of total RNA, accord-
ing to the manufacturer’s instructions. Of a total of 20 μL of the RT reaction, 1 μL was used as
template for amplifications, using primers annealing to the flanking α-globin/FN1 exonic
sequences (α2–3 and Bra2 primers; Fig 2). RT-PCRs were performed under standard condi-
tions using the GoTaq DNA Polymerase (Promega) on a Mastercycler EPgradient (Eppendorf,
Hamburg, Germany).
Competitive-fluorescent RT-PCRs were performed on RNA from transfected cells, using
the same oligonucleotide pair adopted for splicing assays, with the reverse Bra2 primer labelled
with 6-FAM. Amplified fragments were separated on an ABI-3500DX sequencer and quanti-
tated by the GeneMapper v4.0 software (Applied Biosystems). The sum of all fluorescence
peak areas in a single run was set equal to 100%, and the relative quantity of each transcript
expressed as a fraction of the total.
Results
Exome sequencing identified potentially pathogenic AS variants
WES, performed on one affected individual from each of the three families under analysis
(P1-P3, Table 1 and Fig 1), yielded on average 7.7 Gb high-quality sequence data/exome, with
Fig 2. In-vitro analysis of the impact of c.2245-40A>G variant on COL4A5 pre-mRNA splicing. (A) Schematic representation of the hybrid
pBS-KS-COL4A5_ex29 minigene where α-globin exons are represented by light grey boxes, fibronectin (FN1) exons by white boxes, whereas introns
are shown as black lines (not to scale). Exon 29 of COL4A5 is represented by a dark grey box. The c.2245-40A>G mutation in intron 28 is indicated by
a star. Primers used in RT-PCR assays are also indicated. (B) On the left, agarose gel (2%) electrophoresis of RT-PCR products obtained from RNA of
HEK293 cells transfected with the wild-type (wt) or mutant (mut) minigene vector. M: molecular weight marker (pUC9-HaeIII). In the middle,
GeneMapper windows show fluorescence peaks corresponding to the molecular species amplified by RT-PCR. Grey shaded peaks correspond to the
RT-PCR-labeled products, whose relative quantitation is reported on the right of the panel (%). Unshaded peaks represent the size standard (ROX-500
HD). The x axis indicates fluorescence units. On the right, schematic representation of the splicing products, as verified by Sanger sequencing. The
length of each fragment is shown.
https://doi.org/10.1371/journal.pone.0178630.g002
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99.6% target coverage and a 90X mean coverage depth (S2 Table). We focused data analysis on
known Alport genes only, and verified that all exons of COL4A3,COL4A4, and COL4A5were
adequately covered by WES (S1 Fig). The less covered exon was COL4A3 exon 1, with a mean
coverage of 31X, 16X, and 42X in P1, P2, and P3, respectively. Specific analysis of rare variants
(MAF0.01) within AS genes, including all intronic variants, identified a candidate patho-
genic variant in each patient (S3 Table).
P1 is a 47-year-old woman with history of hematuria and slight proteinuria. Diagnosis of
AS was made on the basis of kidney biopsy. She referred that several relatives on her mother’s
side had renal problems and/or died for end-stage renal disease, although her mother does not
show an overt renal phenotype, apart from microhematuria. The proband’s daughter (cur-
rently 21 y.o.) has hematuria, developed proteinuria at age 8, which is progressively worsening,
and also presented with sensorineural hearing loss (SHL) with onset in the first decade. WES
data analysis detected a novel heterozygous A-to-G transition (NM_000495.4:c.2245-40A>G)
within COL4A5 intron 28, 40 nucleotides upstream of exon 29. The variant is present in P1’s
mother and daughter, whereas it is absent in her unaffected siblings (Fig 1A). The peculiar
location of this variant suggested it might affect the branch-point sequence, a conserved signal
important for spliceosome assembly and lariat formation.
The male P2 proband, who is currently 20 years old, started to show microhematuria and
episodes of macrohematuria with proteinuria at age 3; renal biopsy evidenced thinning, thick-
ening, and splitting of the GBM, supporting a diagnosis of AS. Proteinuria has progressively
worsened, with current ratio of proteinuria/creatinuria >2. He has chronic kidney disease
with glomerular filtration rate (GFR)<50 ml/min. He developed SHL at age 10. No ocular
signs are present. The proband’s mother presented with urinary anomalies (microhematuria
and proteinuria) and SHL, but normal renal function. The proband’s grandmother only
showed microhematuria.
WES data analysis identified a novel COL4A5missense variant within exon 33
(NM_000495.4:c.2822G>A), causing the substitution of glycine 941 with an aspartic acid
(p.Gly941Asp). The variant is present in the hemizygous state in the proband as well as in
the affected male cousin (IV1), and in the heterozygous state in all affected female relatives
(Fig 1B). In addition, the identified missense variant is absent both in an in-house database
of ~3,500 ethnically-matched control exomes and in the ExAC browser (http://exac.
broadinstitute.org/, last accessed October 2016), suggesting that it likely represents a private
mutation. The NM_000495.4:c.2822G>A variant affects an evolutionary-conserved residue
and is predicted to be damaging by 10 out of 10 commonly used programs to predict the del-
eteriousness of an amino acid substitution (S2 Fig). Indeed, glycine substitutions within the
repetitive triplet sequence (Gly)-X-Y of the collagenous domain represent one of the most
common type of pathogenic variant found in AS patients, as they are suspected to introduce
kinks in the molecule, thus interfering with the proper folding of the collagen triple helix
[2]. Notably, a different missense mutation affecting the same amino acid, c.2821G>T (p.
Gly491Cys), was previously reported [23,24].
P3 is a 25-year-old woman with family history of isolated microhematuria. She first pre-
sented with microhematuria at age 2 and subsequently developed proteinuria at 7, which has
been progressively worsening. Renal biopsy was diagnostic for AS. At the end of the first
decade, she developed SHL and she is wearing bilateral hearing aids. At 21, routine ophthal-
mic evaluation evidenced a slight maculopathy, characterized by macular flecks, which has
remained stable ever since.
WES showed that P3 carries a homozygous deletion in COL4A3 on chromosome 2
(NM_000091.4:c.30_53del:p.Val11_Leu18del or NM_000091.4:c.40_63del24:p.Leu14_Leu21-
del). The variation was found in the heterozygous state in the mother (II5), who suffers from
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micro-hematuria (Fig 1C). No overt consanguinity was reported, even though a run of homo-
zygosity, spanning >18 Mb from gene EPHA4 to gene PRR21, was found on chromosome 2.
We ruled out the presence of a large deletion on the second allele in the proband by quantita-
tive real-time PCR (data not shown), but we could not exclude a partial uniparental disomy.
This 24-bp in-frame deletion in exon 1 is annotated as a rare low-quality variant (minor allele
frequency, MAF = 0.047%) in the ExAC browser (the site is covered in <80% of analyzed indi-
viduals) and is present in dbSNP147 with two different accession numbers (rs774798108 or
rs876657397). This deletion has been previously and repeatedly reported in AS patients [25–
28]. The 24-bp deletion would eliminate 8 amino acids from the signal peptide, possibly alter-
ing COL4A3 protein secretion, as predicted by three different programs (S3 Table).
The c.2245-40A>G variant in COL4A5 affects exon 29 splicing by
abolishing the branch site
The COL4A5 intronic variant identified in Family 1 (NM_000495.4:c.2245-40A>G) occurs in
a region compatible with exon 29 branch site. According to in-silico predictions performed
with Human Splicing Finder, the wild-type residue corresponds to the best-scoring branch-
point site in the region comprised between nucleotides -20 to -40 upstream of exon 29 accep-
tor splice site, although it does not reach the software threshold for significance (i.e. 67). How-
ever, the c.2245-40A>G substitution significantly decreases the score of the potential branch
site, from 59.27 to 29.64, suggesting that this variant might impact on exon 29 recognition.
Given the unavailability of a suitable biological specimen from the patient to extract RNA,
COL4A5 exon 29, with the surrounding intronic sequences, was cloned, either in the wild-
type or in the mutant version, into a pBS-KS_modified hybrid minigene vector (Fig 2A). The
obtained constructs (pBS-KS-COL4A5_ex29_wt and pBS-KS-COL4A5_ex29_mut) were tran-
siently transfected into human renal HEK293 cells, and COL4A5 splicing was analyzed by
reverse-transcription (RT)-PCR. All amplified fragments were then subjected to direct
sequencing to characterize aberrant splicing events. Furthermore, relative quantitation of all
splicing isoforms was performed by competitive-fluorescent RT-PCRs. Transfection with the
mutant vector originated two aberrant products: the most abundant (93.9%) resulting from
the skipping of exon 29, and the other one (6.1%) resulting from the inclusion of a shorter
exon 29, caused by the activation of an exonic cryptic 3’ acceptor site (Fig 2B). No residual
wild-type splicing was detected. Exon 29 skipping was also present in a fraction (27.7%) of
transcripts derived from the wild-type construct. Both the skipping of exon 29 and the inclu-
sion of the shorter exon 29 are predicted to cause frameshifts leading to the introduction of a
premature stop after 767 or 776 amino acids, respectively.
Phenotypic variability within Family 1 correlates with skewed inactivation
of the mutant allele
Since the three female carriers of the branch-point NM_000495.4:c.2245-40A>G variant
showed different severity of phenotypic manifestations (Fig 1A), we investigated the possibility
that these differences might be due to skewed X-inactivation. Hence, to evaluate the methyla-
tion status of the two alleles, we performed a methylation-sensitive restriction-enzyme assay
on DNA extracted from patients’ blood and then we discriminated the wild-type from the
mutant allele using a polymorphic marker cosegregating with COL4A5, for which the tested
females were heterozygous (Supporting Methods). The results showed a skewed inactivation
(91%) of wild-type COL4A5 allele in IV1, a balanced inactivation of both alleles in III3 (45 vs
55%), and a greater inactivation (89%) of the mutant COL4A5 allele in II2 (S3 Fig), nicely cor-
relating with the progressively milder phenotypic manifestations.
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The 24-bp deletion in COL4A3 affects the signal peptide
To demonstrate that the NM_000091.4:c.30_53del (or c.40_63del) variant alters the physio-
logic COL4A3 signal peptide, we performed localization assays in HEK293 cells using a hybrid
fluorescent reporter protein (hybEGFP, Enhanced Green Fluorescent Protein) containing at
the N-terminus either the complete COL4A3 signal peptide (amino acids 1–29) or the partially
deleted localization signal (Val11_Leu18del). Our results show a clear difference in hybEGFP
subcellular localization in the presence of the deleted COL4A3 signal peptide compared to the
wild type (Fig 3). In particular, hybEGFP fused with the mutant peptide lacking 8 amino acids
displays a diffuse and uniform localization in the cytoplasm and in the nucleus, similarly to the
soluble EGFP (Fig 3). On the contrary, COL4A3-SP-wt-hybEGFP shows a more punctate dis-
tribution within the cytoplasm, compatible with localization along the secretory pathway. Co-
localization assays using either a marker of the endoplasmic reticulum (the calnexin protein),
or a marker of the Golgi apparatus (Trans-Golgi Network protein 38, TGN38) seem to support
this hypothesis (S4 Fig).
Discussion
Here we used WES -together with functional studies- to provide three AS families with a
molecular diagnosis after years of inconclusive results, highlighting non-obvious pathogenic
variants that escaped previous screenings.
The identification of the COL4A5 branch-point variant represented a diagnostic challenge
primarily for its location. Indeed, in routine molecular testing (Sanger sequencing-based)
there is no clear guideline for the intronic regions to include in the screening [29]. Consensus
splice sites and surrounding nucleotides (+1 to +6 and –10 to –1 bp) are usually analyzed,
whereas branch points often are not. The same holds true when NGS approaches are applied
in diagnostic settings [30–32]. Hence, disease-causing variants residing in other intronic loca-
tions (including the branch point) may go undetected, unless an analysis on patient’s RNA is
performed [33,34]. In addition, branch points are difficult to predict on the basis of the nucleo-
tide sequence alone, due to weakly-conserved consensus sequences [35], and to the absence,
until very recently, of experimentally-generated genome-wide datasets of human branch sites
[36].
Branch-point selection is an early step in the splicing process that defines the 3’ acceptor
site and leads to inclusion of the downstream exon in the mature mRNA [37]. Mutations
that affect the branch-point sequence, particularly the branch-point adenine or the common
uridine 2 nucleotides upstream of it (UNA motif), can result in exon skipping or other
aberrant splicing events [38]. Here, we identified a COL4A5 intronic variant in Family 1
(NM_000495.4:c.2245-40A>G) that likely represents the branch-point nucleotide required for
lariat formation and correct inclusion of exon 29. Although prediction programs failed to rec-
ognized it as a reliable branch site, its location is compatible with the distance of the branch-
point adenine from the 30 splice acceptor, which, for the 90% of branch points, is within 39
nucleotides [36]. Moreover, the affected residue (hg19, chrX:107849932) is conserved across
vertebrates (Phastcons score = 1). Finally and most convincingly, we showed abnormal
COL4A5mRNA splicing in the presence of the NM_000495.4:c.2245-40A>G substitution,
using an in-vitro splicing assay. To our knowledge, this is the first report of a branch-site muta-
tion in AS genes, and adds to the relatively small number of branch point-sequence lesions
identified as genetic causes of human diseases [34,38–40]. Indeed, only five ClinVar SNPs
deleting branch points are annotated in OMIM [41].
On the other hand, the identification of the 40_63del variant within exon 1 of COL4A3 in
Family 3 represented a diagnostic challenge mainly for technical reasons. COL4A3 exon 1 is
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extremely GC-rich (77%), and has been reported to be difficult to screen with benchtop NGS
sequencers such as the Ion PGM [8]. Actually, it was not amplified and analyzed in previous
COL4A3-targeted NGS analysis on our patient. In our WES data, COL4A3 exon 1 was the
least covered exon among the three type IV collagen genes (S1 Fig). A second issue relating
to this specific mutation is its correct mapping and nomenclature. Due to the repetitive nature
of the affected sequence, the deletion could be aligned to the reference genome sequence
in two ways, leading to different naming: NM_000091.4:c.30_53del:p.Val11_Leu18del or
NM_000091.4:c.40_63del:p.Leu14_Leu21del (S5 Fig). Each of these annotations is associated
Fig 3. Functional characterization of the signal peptide deletion in COL4A3. Single confocal sections of HEK293 cells expressing
EGFP N-terminus fused either with the entire COL4A3 signal peptide (SP-wt-hybEGFP, top panels) or the 8-amino-acid deleted signal
peptide (SP-del-hybEGFP, middle panels). Positive control cells, expressing a soluble EGFP (pEGFP-N1) are also shown (bottom
panels). DAPI, 4’,6-diamidino-2-phenylindole; EGFP, Enhanced green fluorescent protein. Scale bar: 10 μm.
https://doi.org/10.1371/journal.pone.0178630.g003
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with a different dbSNP 147 accession number (rs774798108 or rs876657397), although com-
monly used genome browsers (UCSC, https://genome.ucsc.edu/, and ENSEMBL, http://www.
ensembl.org/, last accessed 30 December 2016) only report the rs774798108 variant, which
lacks clinical annotation; conversely, rs876657397 is annotated as a pathogenic allele (OMIM:
120070.0011; ClinVar: 192299). We hypothesize that the first annotation derives from auto-
mated short-read alignment of NGS data, whereas the second possibly resulted from inspec-
tion of electropherograms obtained by Sanger sequencing, and conforms to the Human
Genome Variation Society (HGVS) recommendations for the description of sequence variants
(http://varnomen.hgvs.org). Indeed, over the years, the 40_63del variant was repeatedly
reported in AS patients of different ethnic origins. It was first described in the heterozygous
state in an Italian patient with history of microhematuria and mild proteinuria [25]. Subse-
quently, it was found in one Spanish patient [26] and four Chinese patients [27] with autoso-
mal recessive AS: in four of them, the mutation was present in compound heterozygosity with
other pathogenic mutations [26,27], whereas in the fifth patient it was present in the homozy-
gote state, despite no reported consanguinity [27]. More recently, the same in-frame deletion
was identified as a founder mutation in Ashkenazi Jews, with an estimated carrier frequency of
1:183 [28]. In the heterozygous state, the 40_63del mutation in COL4A3 seems to cause little or
no renal dysfunction, whereas in the homozygous state or combined, on the other allele, with
another loss-of-function mutation, it results in severe AS with hearing loss and, as in the case
of our proband, ocular anomalies.
From a purely genetic point of view, there is little doubt on the pathogenicity of this vari-
ant; however, at the moment, automated alignment and annotation could lead to miss its
correct identification as pathogenic. We hence suggest to make uniform and to update the
nomenclature for this variant, possibly merging the two annotations, to avoid misleading
interpretations of its clinical relevance. In addition, we provide for the first time a functional
characterization of this mutation demonstrating that it alters the COL4A3 signal peptide,
thus adding a further level of evidence for pathogenicity. Due to the recurrence of this spe-
cific variant in different populations, it would be important to screen specifically COL4A3
exon1 whenever a diagnosis of autosomal recessive AS and/or familiarity for isolated micro-
hematuria is suspected.
In conclusion, we demonstrated how a diligent application of exome-sequencing data anal-
ysis combined with an accurate experimental validation are critical to solve elusive cases in the
molecular genetic diagnosis of AS. This concept is valid for most human genetic diseases and
is becoming increasingly important in the P4 (Personalized, Predictive, Preventive, Participa-
tory) medicine era.
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